Slide 1: Orion Interim Report January─September 2016
Orion Interim Report January─September 2016 25 October 2016 Timo Lappalainen President & CEO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of these strat
Slide 3: Business developed well – capital gains enhanced strong operating profit growth
Business developed well – capital gains enhanced strong operating profit growth • Net sales and operating profit were higher than in comparative period • Operating profit includes about EUR 22 million of capital gains received in Q3 • Proprietary Products and Specialty Products both grew • Orion and
Slide 4: Key figures
Key figures 9M 2015 9M 2016 9M 2015 9M 2016 754 794 1.43 1.20 1.23 1.11 216 256 Net sales, EUR Operating profit, Basic earnings per Cash flow per share million EUR million share, EUR before financial items, EUR +5% +19% +19% +11% 4 25 October 2016 Orion Interim Report January─September 2016
Slide 5: Breakdown of net sales
Breakdown of net sales Group’s net sales in 9M 2016 were EUR 794 million By business division By market area 5% 3% 4% 15% 7% 34% 31% 7% 47% 31% 16% Proprietary Products Specialty Products Animal Health Finland Scandinavia Fermion Other Europe North America Contract manufacturing & other Orion Diagno
Slide 6: Business Reviews
Business Reviews
Slide 7: Pharmaceuticals business
Pharmaceuticals business 9M 2015 9M 2016 Net sales split 9M 9M 754 EUR million 2016 2015 Change % 714 Proprietary Products 269 244 +10% Specialty Products 372 339 +10% Animal Health 54 59 -10% Fermion 33 43 -24% 217 257 Contract manufacturing & other 27 28 -1% • Total sales of Proprietary Products g
Slide 8: Best-selling pharmaceuticals 9M 2016
Best-selling pharmaceuticals 9M 2016 Net sales Change vs. Product Indication EUR million 9M 2015 Parkinson’s disease 102 -9% Asthma, COPD 47 +28% Acute decompensated heart 41 +9% failure Intensive care sedative 41 +26% Rheumatoid arthritis, 31 +86% inflammatory bowel diseases Inflammatory pain 17 -2
Slide 9: Orion clear market leader in Finland
Orion clear market leader in Finland Finnish human pharmaceuticals Finland’s biggest pharmaceutical market in 9M 2016 companies in 9M 2016 EUR million Wholesale, EUR million 250 217 1,620 200 Orion’s market +4% share 13% 1,680 150 Orion in Finnish human 100 94 75 88 pharmaceuticals market, 76 EUR mi
Slide 10: Specialty Products growing strongly in Scandinavia
Specialty Products growing strongly in Scandinavia Net sales in key market areas in Net sales Change 9M 2016 (EUR million) 9M 2016 vs. TOP 3 Products EUR million 9M 2015 Vs. 9M Scandinavia 31 +86% 2015 60 +19% 17 -2% Vs. 9M Finland 14 +0% 2015 218 +8% • Clear slowing of Remsima growth since early in
Slide 11: Parkinson's drugs
Parkinson’s drugs 60 Sales of Orion’s branded Parkinson drugs by market area 50 MAT6/2016* 3% 40 EUR million 30 25% Europe 20 48% Japan 10 ROW USA 0 24% Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3 2013 2014 2015 2016 *Source: IMS Health sales statistics MAT6/2016 Deliveries to Novartis Orion's own sales 11 25 Oc
Slide 12: Easyhaler product family and Simdax
Easyhaler® product family and Simdax® Simdax 18 16 16 14 14 12 12 EUR million EUR million 10 10 8 8 6 6 4 4 2 2 0 0 Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2013 2014 2015 2016 2013 2014 2015 2016 Others Bufomix Easyhaler Simdax 12 25 October 2016 Orion Interim Rep
Slide 13: Dexdor intensive care sedative
dexdor® intensive care sedative European sedative market MAT6/2016* Dexdor sales Total market value EUR 530 million (+4%) 16 12% 14 8% 12 10 EUR million 14% 8 66% 6 4 Propofol EUR 350 million (+4%) 2 Midazolam EUR 73 million (-3%) 0 Dexmedetomidine EUR 41 million (+26%) Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q
Slide 14: Key clinical pharmaceutical development projects 1/2
Key clinical pharmaceutical development projects 1/2 Project Indication PHASE Registration Easyhaler® budesonide-formoterol 1) Asthma, COPD I II III Registration Easyhaler® salmeterol-fluticasone 2) Asthma, COPD I II III Prostate cancer ODM-201 (androgen receptor antagonist) 3) (nmCRPC) I II III Pro
Slide 15: Key clinical pharmaceutical development projects 2/2
Key clinical pharmaceutical development projects 2/2 Project Indication PHASE Registration ODM-104 (more effective COMT inhibitor) Parkinson’s disease I II ODM-203 (targeted FGFR+VEGFR inhibitor) Solid tumours I II ODM-207 (BET protein inhibitor) Cancer I ODM-204 (CYP17 enzyme and androgen receptor
Slide 16: Diagnostics business
Diagnostics business • QuikRead® tests remained the 9M 2015 9M 2016 main product 43 • Launching of the first Orion 41 GenRead® test system products continued 6.8 6.6 Net sales, Operating profit, EUR million EUR million -3% -2% 16 25 October 2016 Orion Interim Report January─September 2016
Slide 17: Outlook for 2016 (updated on 15 June 2016)
Outlook for 2016 (updated on 15 June 2016) Net sales are estimated to be slightly higher than in 2015 Net sales (net sales were EUR 1,016 million in 2015). Operating profit excluding possible capital gains is Operating profit estimated to exceed EUR 270 million (operating profit was EUR 267 million
Slide 18: Orion Calendar 2017
Orion Calendar 2017 Financial Statement Release for 2016 Wed 8 Feb 2017 Planned to be held on Annual General Meeting 2017 Wed 22 Mar 2017 Interim Report January─March 2017 Wed 26 Apr 2017 Half-Year Financial Report January─June Wed 19 Jul 2017 2017 Interim Report January─September 2017 Thu 26 Oct 20
Slide 19: Orion – Building well-being
GRION Building well-being